HGH Fragment 176-191 Research & Listing Availability
Current HGH Fragment 176-191 vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
Current HGH Fragment 176-191 vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
About HGH Fragment 176-191
Pre-clinical / research-onlyAlso known as: HGH Frag 176-191 · AOD9401 · Tyr-hGH 177-191HGH Fragment 176-191 is the fat-mobilizing C-terminal fragment of human growth hormone, most often sourced for lipolysis and body-composition research. It ships as a lyophilized powder you reconstitute with bacteriostatic water, and is closely related to — but not identical to — the tyrosine-extended analog AOD-9604, which is the version that actually reached human trials.[1]
What to check before you buy HGH Fragment 176-191:
- A third-party COA with mass-spec confirmation of the 16-amino-acid 176-191 sequence — important because this fragment is frequently conflated with the tyrosine-extended AOD-9604, and the two are not interchangeable.
- A COA showing ≥98% purity by HPLC, dated within the last 6–12 months and matching the exact vial size and batch.
- Accurate vial fill: a labeled 5mg vial should assay close to 5mg. Under-filled vials are a common failure mode that skews your reconstitution math.
Pre-clinical work demonstrated reduced adipose mass, increased fat oxidation, and absence of hyperglycemia in obese rodent models.[2] The tyrosine-extended analog (AOD-9604) reached a 12-week Phase 2b trial in obese adults (Heffernan / Ng programs), reporting modest weight loss vs. placebo before the program was halted.[3] The non-tyrosylated 176-191 fragment itself has not been the subject of a published controlled human trial.
Regulatory: Not FDA-approved. Clinical development discontinued in 2007. Sold as a research peptide only.
HGH Fragment 176-191: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how HGH Fragment 176-191 works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
HGH Fragment 176-191 is the C-terminal 16-residue fragment of recombinant human growth hormone, isolated and characterised by F.M. Ng and colleagues at Monash University in the late 1990s and early 2000s as part of a programme to separate growth hormone's fat-mobilising activity from its growth-promoting activity.[1] The premise of that programme was that native growth hormone exerts its lipolytic effect through a distinct C-terminal domain that does not require IGF-1 induction or the classical JAK2/STAT5 signalling cascade triggered by GH-receptor dimerisation on hepatocytes — so a stripped-down fragment containing only the lipolytic domain should mobilise fat without producing the IGF-1-mediated tissue growth, insulin antagonism, or hyperglycaemia that limit chronic full-length GH use.[2] Pre-clinical work in obese mouse models supported the separation: HGH Fragment 176-191 reduced adipose mass and increased fat oxidation without raising fasting glucose or producing the organ-overgrowth phenotype seen with full-length GH.[2] AOD-9604 is the closely related tyrosine-extended analog (Tyr-hGH 177-191) advanced into clinical development by Metabolic Pharmaceuticals; the tyrosine residue was added to enable simple radiolabelling for pharmacokinetic work, and AOD-9604 has been the version actually tested in published human studies.[1][3] Both molecules have very short plasma half-lives (minutes), are typically dosed subcutaneously, and crucially the *non-tyrosylated* 176-191 fragment sold by research-peptide suppliers has never been the subject of a published controlled human trial in its own right — all of the human-tolerability data published to date come from AOD-9604.[3] HGH Fragment 176-191 is banned by the World Anti-Doping Agency under Section S2 of the WADA Prohibited List.[4]
Active research areas
- Pre-clinical lipolysis and rodent obesity modelsThe foundational rodent work by Heffernan, Ng and colleagues demonstrated that chronic dosing with the lipolytic C-terminal fragment reduced adipose mass and increased lipid oxidation in obese mice and beta-3-adrenoceptor-knockout mice without the hyperglycaemia or insulin-antagonism seen with full-length GH — the central evidence that the fat-mass and growth effects of GH can be molecularly separated.[1][2]
- AOD-9604 Phase 2b obesity programme (discontinued)Metabolic Pharmaceuticals advanced AOD-9604 through a 12-week Phase 2b trial in obese adults that reported modest placebo-adjusted weight loss; the broader Phase 2 development programme was discontinued in 2007 because the magnitude of effect was not commercially compelling against contemporaneous obesity-drug candidates, and no AOD-9604 sponsor has restarted the programme since.[3]
- Human safety and tolerability (AOD-9604 only)Stier and colleagues summarised the human safety record for AOD-9604 across the Metabolic Pharmaceuticals dossier — short-half-life subcutaneous dosing was well tolerated with no signal of IGF-1 induction, hyperglycaemia, or organ overgrowth.[3] All published human data are on AOD-9604, not the non-tyrosylated 176-191 fragment.
- Repositioning as a topical/oral nutraceutical (Calzada)After Phase 2b discontinuation, the AOD-9604 IP was eventually licensed for low-dose oral and topical formulations sold as joint/skin nutraceuticals; this is an off-label commercial repositioning rather than a continued obesity drug-development programme, and is not supported by Phase 3 efficacy data.[5]
- Anti-doping detectionWADA lists GH fragments including AOD-9604 under Section S2 of the Prohibited List, so anti-doping laboratories maintain detection methods even though no major sport has reported a positive case for the molecule.[4]
Open questions & leading hypotheses (3)
- Hypothesis: Subcutaneous HGH Fragment 176-191 at community-protocol doses (250–500 µg/day) produces meaningful fat loss in healthy adults.Evidence: Pre-clinical rodent studies clearly demonstrated lipolytic activity for the C-terminal fragment.[1][2] Counter-evidence: the AOD-9604 Phase 2b human trial reported only modest placebo-adjusted weight loss — small enough that the sponsor halted development for lack of commercial viability — and the non-tyrosylated 176-191 fragment has never been tested in a published controlled human trial in its own right.[3] Translating rodent fat-mobilisation results to a meaningful human fat-loss claim is not supported by the human-trial record.
- Hypothesis: HGH Fragment 176-191 produces fat loss without the IGF-1 elevation, insulin antagonism, or hyperglycaemia that limit chronic full-length GH use.Evidence: The molecular rationale for the fragment is precisely this separation, and the AOD-9604 Phase 2 dossier reported no IGF-1 induction or glucose-tolerance disruption across the dose range tested.[1][2][3] Counter-evidence: the human data are limited to a single discontinued Phase 2b programme, and absence of evidence at small doses over 12 weeks is not the same as evidence of absence at higher doses over longer periods.
- Hypothesis: Research-grade HGH Fragment 176-191 sold by peptide suppliers is pharmacologically equivalent to AOD-9604, so the AOD-9604 human safety record extrapolates to it.Evidence: The two molecules differ only by an N-terminal tyrosine added for radiolabelling, and rodent lipolysis assays for both gave broadly comparable results.[1][2] Counter-evidence: no published study has directly compared their pharmacokinetics, receptor pharmacology, or dose-response in humans, so the extrapolation is structural rather than empirical.
What community users report
Anecdotal — not controlled-trial evidence
On r/Peptides and r/PeptideAdmin, HGH Fragment 176-191 is run almost exclusively in fat-loss contexts at 250–500 µg subcutaneous per day, typically split AM/PM and often timed pre-cardio or fasted, and frequently stacked with CJC/Ipamorelin blends, semaglutide/tirzepatide, or AOD-9604 itself.[6][7] Reported subjective effects are modest and variable: a subset of users describe a measurable acceleration of fat loss on top of an established calorie deficit; an equally large subset reports no perceived difference versus the same calorie deficit alone, consistent with the small effect size seen in the AOD-9604 Phase 2b trial.[3] Side effects are infrequently described and typically limited to mild injection-site soreness and transient fatigue. **All community reports are anecdotal and have not been validated in controlled trials.** The non-tyrosylated 176-191 fragment specifically has no published controlled human dose-response or chronic-use safety data of its own — the entire human evidence base for the molecular class is the AOD-9604 dossier, and that dossier supports a tolerable safety profile but a small, commercially-unviable efficacy signal.
Sources & references (7)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Ng FM et al. Metabolic studies of a synthetic lipolytic domain (AOD9401) of human growth hormone. Horm Res 2000;53:274–278. · PMID: 11146367 link
- [2]Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice. Endocrinology 2001;142:5182–5189. · PMID: 11713213 link
- [3]Stier H et al. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab 2013;3:7–15. link
- [4]World Anti-Doping Agency — 2024 Prohibited List, Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — covers GH and GH fragments including AOD-9604. link
- [5]Wijaya YT et al. Growth hormone and its lipolytic and anti-lipolytic effects: contribution of the C-terminal domain to fat-mass regulation — review of the lipolytic-fragment programme. (Secondary review; cite the underlying Ng/Heffernan papers for primary data.) link
- [6]Community report — r/Peptides AOD-9604 / HGH Fragment 176-191 fat-loss protocol threads (subreddit), accessed May 2026. link
- [7]Community report — r/PeptideAdmin HGH Fragment 176-191 dosing and stacking discussions (subreddit), accessed May 2026. link
HGH Fragment 176-191 Calculator Input Observations
In lifetime HGH Fragment 176-191 calculator inputs, 1mg is the most frequent entered amount (57 of 233 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (18 of 26 lifetime frequency responses, across entered amounts). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length.
About HGH Fragment 176-191
HGH Fragment 176-191 is the fat-mobilizing C-terminal fragment of human growth hormone, most often sourced for lipolysis and body-composition research. It ships as a lyophilized powder you reconstitute with bacteriostatic water, and is closely related to — but not identical to — the tyrosine-extended analog AOD-9604, which is the version that actually reached human trials.
HGH Fragment 176-191 is tracked under the Weight Loss category on WPA. Its reported half-life is ~30 min. Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved.
Frequently Asked Questions: HGH Fragment 176-191
Are current HGH Fragment 176-191 offers available?
Current HGH Fragment 176-191 vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
What can I check if HGH Fragment 176-191 listings become available?
Check the exact compound, format, labelled quantity, named laboratory, test date, and batch match. Confirm any future listing price, discount terms, and stock directly with the vendor. Catalog COA fields alone are not independent verification.
Does research activity establish current HGH Fragment 176-191 availability?
No. Search interest, calculator entries, historical prices, related compounds, and other formats do not establish current offers in this comparison. Research information and navigation to other compounds remain available.